Citigroup’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-2,092
| Closed | -$32K | – | 5013 |
|
|
2022
Q2 | $32K | Sell |
2,092
-30
| -1% | -$459 | ﹤0.01% | 4061 |
|
|
2022
Q1 | $38K | Sell |
2,122
-3,045
| -59% | -$54.5K | ﹤0.01% | 4137 |
|
|
2021
Q4 | $123K | Sell |
5,167
-958
| -16% | -$22.8K | ﹤0.01% | 3866 |
|
|
2021
Q3 | $186K | Sell |
6,125
-3,542
| -37% | -$108K | ﹤0.01% | 3417 |
|
|
2021
Q2 | $308K | Buy |
9,667
+1,690
| +21% | +$53.8K | ﹤0.01% | 3358 |
|
|
2021
Q1 | $238K | Buy |
7,977
+172
| +2% | +$5.13K | ﹤0.01% | 3276 |
|
|
2020
Q4 | $248K | Sell |
7,805
-999
| -11% | -$31.7K | ﹤0.01% | 3109 |
|
|
2020
Q3 | $241K | Buy |
8,804
+8
| +0.1% | +$219 | ﹤0.01% | 2686 |
|
|
2020
Q2 | $240K | Sell |
8,796
-1,672
| -16% | -$45.6K | ﹤0.01% | 2987 |
|
|
2020
Q1 | $208K | Sell |
10,468
-2,301
| -18% | -$45.7K | ﹤0.01% | 2832 |
|
|
2019
Q4 | $299K | Buy |
12,769
+1,684
| +15% | +$39.4K | ﹤0.01% | 2927 |
|
|
2019
Q3 | $206K | Sell |
11,085
-390
| -3% | -$7.25K | ﹤0.01% | 3077 |
|
|
2019
Q2 | $242K | Buy |
11,475
+3,902
| +52% | +$82.3K | ﹤0.01% | 3102 |
|
|
2019
Q1 | $159K | Buy |
7,573
+373
| +5% | +$7.83K | ﹤0.01% | 3274 |
|
|
2018
Q4 | $136K | Buy |
7,200
+1,000
| +16% | +$18.9K | ﹤0.01% | 3324 |
|
|
2018
Q3 | $154K | Sell |
6,200
-800
| -11% | -$19.9K | ﹤0.01% | 3304 |
|
|
2018
Q2 | $169K | Buy |
+7,000
| New | +$169K | ﹤0.01% | 3065 |
|
|
2018
Q1 | – | Sell |
-1,000
| Closed | -$24K | – | 4918 |
|
|
2017
Q4 | $24K | Buy |
+1,000
| New | +$24K | ﹤0.01% | 4166 |
|